Skip to main content
. 2022 Mar 31;12:857968. doi: 10.3389/fonc.2022.857968

Figure 8.

Figure 8

SND1 and PGAM5 are potential prognostic markers for HCC patients. (A) Immunoblotting analysis of SND1 and PGAM5 protein levels in 12 pairs of clinically matched adjacent noncancerous liver tissues (Normal) and human liver cancer tissues (Tumor). Calnexin served as loading control. (B) Immunoblotting analysis of SND1 protein levels in Cyt, Nuc, and Mito components purified from tumor tissues of HCC patients. GAPDH, Lamin B1, and TOM20 were used as markers of cytosolic, nuclear, and mitochondrial proteins, respectively. (C, D) mRNA levels of SND1 (C) and PGAM5 (D) were determined in adjacent noncancerous liver tissues (Normal) and liver cancer tissues (Tumor) from The Cancer Genome Atlas (TCGA) database (http://gepia.cancer-pku.cn/). (E, F) Kaplan-Meier analysis of overall survival with log-rank tests for low versus high expression of SND1 or PGAM5 genes in HCC patients (http://gepia.cancer-pku.cn/). (G) SND1 is positively correlated with the expression of PGAM5 in liver cancer tissues based on TCGA cohort. The line indicates linear regression, and Spearman’s rank correlation coefficients (R) and the corresponding p value are indicated.